Nyssa Claire El-Amin
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 13 years
- University of California, San Francisco School of Medicine, 2013
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Nyssa Claire El-Amin’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Medicaid work
$0 in 2018
Medicaid paid $0 for 237 billed services this clinician did in 2018, up to 61 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 15 | $0 |
| Short return visit (20+ min) | 48 | $0 |
| Return visit (30+ min) | 174 | $0 |
| 2018 | 237 | 3 | 61 | $0 |
Drugs they prescribed that Part D paid
$3,532
Pharmacies billed $3,532 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 52) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
49 generic and fewer than 11 brand-name prescriptions · $3,532 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 52 | 23 | 0% (0) | None | $3,532 |
| 2023 | 77 | 26 | None | None | $12,662 |
| 2022 | 53 | 19 | None | None | $2,898 |
| 2021 | 31 | None | None | None | $1,065 |
| 2020 | 71 | None | 16% (11) | None | $1,092 |
| 2019 | 56 | None | 21% (12) | None | $898 |
| 2018 | 80 | 14 | 23% (18) | None | $2,434 |
| 2017 | 362 | 83 | 5% (18) | None | $15,689 |
| 2016 | 1,670 | 131 | 5% (77) | None | $76,327 |
| 2015 | 1,059 | 119 | 5% (57) | None | $43,807 |
| 2014 | 206 | 38 | None | None | $8,109 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 1 drug
| Gabapentin | 11 | $129 | $12 |
2020: 1 drug
| Metoclopramide | 12 | $78 | $6 |
2019: 1 drug
| Mirtazapine | 11 | $426 | $39 |
2018: 2 drugs
| Mirtazapine | 12 | $578 | $48 |
| Gabapentin | 12 | $107 | $9 |
2017: 11 drugs
| Memantine | 14 | $617 | $44 |
| Atorvastatin | 19 | $349 | $18 |
| Levothyroxine | 14 | $290 | $21 |
| Mirtazapine | 12 | $276 | $23 |
| Tamsulosin | 13 | $250 | $19 |
| Gabapentin | 12 | $106 | $9 |
| Sertraline | 20 | $102 | $5 |
| Furosemide | 17 | $95 | $6 |
| Quetiapine | 14 | $84 | $6 |
| Amlodipine Besylate | 13 | $64 | $5 |
| Lisinopril | 12 | $36 | $3 |
2016: 53 drugs
| Lantus Solostar | 11 | $11,662 | $1,060 |
| Januvia | 22 | $7,723 | $351 |
| Lidocaine | 16 | $3,804 | $238 |
| Advair Diskus | 11 | $3,707 | $337 |
| Vesicare | 12 | $3,407 | $284 |
| Memantine | 53 | $2,731 | $52 |
| Hydrocodone-Acetaminophen | 46 | $1,471 | $32 |
| Divalproex | 24 | $1,431 | $60 |
| Mirtazapine | 45 | $1,306 | $29 |
| Proair Hfa | 22 | $1,240 | $56 |
| Quetiapine | 67 | $1,131 | $17 |
| Levothyroxine | 54 | $929 | $17 |
| Potassium Chloride | 32 | $905 | $28 |
| Atorvastatin | 63 | $808 | $13 |
| Baclofen | 12 | $802 | $67 |
| Donepezil | 36 | $705 | $20 |
| Glycopyrrolate | 11 | $554 | $50 |
| Omeprazole | 35 | $535 | $15 |
| Polyethylene Glycol 3350 | 18 | $408 | $23 |
| Sertraline | 81 | $384 | $5 |
| Metoprolol | 14 | $361 | $26 |
| Amlodipine Besylate | 50 | $289 | $6 |
| Lorazepam | 21 | $275 | $13 |
| Gabapentin | 31 | $270 | $9 |
| Tamsulosin | 13 | $269 | $21 |
| Furosemide | 66 | $263 | $4 |
| Fluticasone Propionate | 18 | $243 | $14 |
| Hydralazine | 26 | $233 | $9 |
| Hydroxyzine | 14 | $207 | $15 |
| Finasteride | 18 | $193 | $11 |
| Prednisone | 26 | $186 | $7 |
| Losartan | 25 | $182 | $7 |
| Azithromycin | 14 | $176 | $13 |
| Famotidine | 23 | $171 | $7 |
| Clonidine | 23 | $163 | $7 |
| Glipizide Er | 14 | $157 | $11 |
| Lisinopril | 35 | $142 | $4 |
| Clopidogrel | 14 | $131 | $9 |
| Simvastatin | 14 | $131 | $9 |
| Pantoprazole | 23 | $128 | $6 |
| Clonazepam | 18 | $124 | $7 |
| Levofloxacin | 15 | $111 | $7 |
| Benazepril | 22 | $110 | $5 |
| Citalopram Hbr | 15 | $109 | $7 |
| Cephalexin | 11 | $106 | $10 |
| Ciprofloxacin | 13 | $90 | $7 |
| Amiodarone | 14 | $88 | $6 |
| Warfarin | 11 | $72 | $7 |
| Glipizide | 16 | $72 | $5 |
| Ibuprofen | 11 | $72 | $7 |
| Trazodone | 16 | $68 | $4 |
| Primidone | 12 | $64 | $5 |
| Metformin | 13 | $29 | $2 |
2015: 30 drugs
| Advair Diskus | 16 | $6,566 | $410 |
| Proair Hfa | 17 | $1,126 | $66 |
| Levothyroxine | 53 | $809 | $15 |
| Hydrocodone-Acetaminophen | 23 | $735 | $32 |
| Memantine | 14 | $690 | $49 |
| Mirtazapine | 25 | $539 | $22 |
| Omeprazole | 40 | $477 | $12 |
| Polyethylene Glycol 3350 | 15 | $455 | $30 |
| Quetiapine | 42 | $447 | $11 |
| Metoprolol | 13 | $347 | $27 |
| Potassium Chloride | 13 | $282 | $22 |
| Atorvastatin | 22 | $264 | $12 |
| Lorazepam | 20 | $227 | $11 |
| Lisinopril | 49 | $205 | $4 |
| Gabapentin | 25 | $203 | $8 |
| Donepezil | 19 | $171 | $9 |
| Simvastatin | 32 | $167 | $5 |
| Amlodipine Besylate | 39 | $164 | $4 |
| Clopidogrel | 18 | $152 | $8 |
| Furosemide | 37 | $128 | $3 |
| Fluticasone Propionate | 15 | $120 | $8 |
| Hydralazine | 11 | $107 | $10 |
| Sertraline | 18 | $105 | $6 |
| Metoprolol | 18 | $86 | $5 |
| Prednisone | 11 | $84 | $8 |
| Losartan | 19 | $71 | $4 |
| Benazepril | 20 | $68 | $3 |
| Glipizide | 14 | $65 | $5 |
| Metformin | 16 | $61 | $4 |
| Tramadol | 13 | $51 | $4 |
2014: 4 drugs
| Gabapentin | 17 | $224 | $13 |
| Lisinopril | 22 | $124 | $6 |
| Metformin | 22 | $111 | $5 |
| Simvastatin | 18 | $104 | $6 |
Money from drug and device companies
$181 in 2021
A payment is not proof that care is biased.
| BioDelivery Sciences International | Belbuca | $76 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $59 | 1 payment
|
| Emergent BioSolutions | Narcan | $45 | 1 payment
|
See all 3 published payments
| Emergent BioSolutions | Meals · 2021-09-10 | Narcan | $45 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2021-09-09 | Relistor | $59 |
| BioDelivery Sciences International | Meals · 2021-09-08 | Belbuca | $76 |
Professional record
- NPI
- 1215366851
- Licence
- CA 95000055
- Trained
- University of California, San Francisco School of Medicine, 2013 · 13 years ago
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-11-04
- NPI last updated
- 2025-08-04
- NPI record certified
- 2025-08-04
This is when the NPI record was last certified, not a medical board exam.